Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

origin: oncology genomic testing

A portfolio of Exact genomic solutions that delivers actionable insights on treatment determination and therapy selection to inform personalized decisions.

We're defining a new approach to oncology genomics.

Exact Sciences’ Precision Oncology Portfolio of Tests

Raise your Exactations

with genomic information for each patient’s situation.


Genomic testing can help inform the right cancer treatment decision for you

It's important to know everything you can about genomic tests; that way, you and your doctor can make an informed decision together.

Learn more about genomic testing

Real patients share their stories of inspiration

  • Billing & Coverage

    Exact Sciences believes that everyone should have access to the information they need to make informed decisions about their cancer treatment. That’s why we offer the Genomic Access Program (GAP) to help patients navigate the insurance and billing process.

    We’ve set the Exactations high

    Over 1 million patients benefited from Oncotype DX® tests

    Helping them avoid over/undertreatment in breast, prostate, and colon cancers.